Deal driver

BeiGene’s $750M offering could jump-start Chinese bellwether’s in-licensing plans

A $750 million offering from BeiGene Ltd. (NASDAQ:BGNE) should give the Chinese biotech enough financial firepower to accelerate its new in-licensing strategy and position itself as a partner of choice for innovative cancer therapies.

BeiGene raised its follow-on on Jan. 18 through

Read the full 424 word article

User Sign In